217 related articles for article (PubMed ID: 32421883)
1. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
[TBL] [Abstract][Full Text] [Related]
2. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
3. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
4. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Pawlyn C; Melchor L; Murison A; Wardell CP; Brioli A; Boyle EM; Kaiser MF; Walker BA; Begum DB; Dahir NB; Proszek P; Gregory WM; Drayson MT; Jackson GH; Ross FM; Davies FE; Morgan GJ
Blood; 2015 Jan; 125(5):831-40. PubMed ID: 25428216
[TBL] [Abstract][Full Text] [Related]
5. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
6. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
7. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
9. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
Fonseca R; Debes-Marun CS; Picken EB; Dewald GW; Bryant SC; Winkler JM; Blood E; Oken MM; Santana-Dávila R; González-Paz N; Kyle RA; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR
Blood; 2003 Oct; 102(7):2562-7. PubMed ID: 12805059
[TBL] [Abstract][Full Text] [Related]
10. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.
Butler C; Wolff DJ; Kang Y; Stuart RK; Costa LJ
Leuk Lymphoma; 2012 Dec; 53(12):2444-8. PubMed ID: 22574971
[TBL] [Abstract][Full Text] [Related]
11. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
Chang H; Sloan S; Li D; Zhuang L; Yi QL; Chen CI; Reece D; Chun K; Keith Stewart A
Br J Haematol; 2004 Apr; 125(1):64-8. PubMed ID: 15015970
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.
Sato S; Kamata W; Okada S; Tamai Y
Int J Hematol; 2021 Feb; 113(2):207-213. PubMed ID: 32949373
[TBL] [Abstract][Full Text] [Related]
13. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
Bal S; Giri S; Godby KN; Costa LJ
Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
[No Abstract] [Full Text] [Related]
14. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
15. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
16. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
[TBL] [Abstract][Full Text] [Related]
17. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
18. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
19. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.
Miura K; Iida S; Hanamura I; Kato M; Banno S; Ishida T; Kusumoto S; Takeuchi G; Miwa H; Nitta M; Inagaki H; Eimoto T; Nomura K; Taniwaki M; Ueda R
Cancer Sci; 2003 Apr; 94(4):350-4. PubMed ID: 12824903
[TBL] [Abstract][Full Text] [Related]
20. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
